A client who has attempted suicide has an underlying diagnosis of depression. Based on the biochemical function that is most associated with suicidal behavior, the nurse anticipates which medication classification will be ordered for the client?

Choice A reason: Suicide in depression is linked to low serotonin, impairing prefrontal cortex regulation and increasing impulsivity. SSRIs increase serotonin, stabilizing amygdala-prefrontal circuits, reducing suicidal ideation by enhancing mood regulation and impulse control, making them the first-line treatment. Choice B reason: Atypical antipsychotics target dopamine and serotonin receptors for psychosis or mania, not primary suicide risk. Depression-related suicide stems from serotonin deficits, and antipsychotics are less effective for this neurochemical profile, making them inappropriate as first-line treatment. Choice C reason: Mood stabilizers like lithium address bipolar mood swings, not primary depression-related suicide. Serotonin dysregulation drives suicidal behavior in depression, and stabilizers lack direct serotonin enhancement, making them less effective than SSRIs for this indication. Choice D reason: Tricyclic antidepressants increase serotonin and norepinephrine but have higher side effect risks, like cardiotoxicity, compared to SSRIs. Serotonin deficits drive suicide risk, and SSRIs are safer and more effective for targeting this neurochemical imbalance in depression.